Ronald Aldridge
Plus aucun poste en cours
Profil
Ronald Aldridge worked as a Senior Director of Investor Relations at PAREXEL International Corp.
from 2016 to 2017.
He also worked as the Head of Investor Relations at The Nassau Cos.
of New York, Inc. and as an Investor Relations Contact at Constellation Pharmaceuticals, Inc.
Anciens postes connus de Ronald Aldridge
| Sociétés | Poste | Fin |
|---|---|---|
| PAREXEL INTERNATIONAL CORPORATION | Investor Relations Contact | 01/10/2017 |
| CONSTELLATION PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| THE PHOENIX COMPANIES, INC. | Public Communications Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
PAREXEL International Corp.
 PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
The Nassau Cos. of New York, Inc.
 The Nassau Cos. of New York, Inc. Life/Health InsuranceFinance The Nassau Cos. of New York, Inc. is a holding company, offers annuities and life insurance services. Its products include life insurance, annuities, product prospectuses and application and forms. The company was founded in 1851 and is headquartered in Hartford, CT. | Finance |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
